Delenex Therapeutics Completes its Management Team

ZURICH-SCHLIEREN, SWITZERLAND--(Marketwire - September 01, 2011) -

Delenex Therapeutics AG /

Delenex Completes its Management Team

Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

Zürich-Schlieren, Switzerland, Sept 1, 2011. Delenex Therapeutics AG ("Delenex") announces the appointment of Thomas Jung, MD, as its Chief Medical Officer.

Thomas Jung brings significant experience in medical research and clinical development to Delenex. A board certified dermatologist, he has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel. In January 2008 he took the leadership of the Ilaris® development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.

Eric de La Fortelle, CEO of Delenex, said "With the arrival of an experienced clinician, initially trained in dermatology but with significant clinical development experience in several other therapeutic areas, notably autoimmunity, gastroenterology, respiratory, neurosciences and musculoskeletal disorders, Delenex is able to do full justice to its powerful discovery platform, and implement the best clinical programs to rapidly bring its major new compounds to clinical proof of concept. We are happy and proud to welcome him in the company."

Thomas Hecht, Chairman of the Board, commented: "Delenex is very pleased to welcome Thomas at its Management Board. Thomas brings all the clinical and strategic skills to Delenex which are needed to advance our products from preclinical into and through clinical stages of development. The ability of Delenex to attract senior leaders from the pharmaceutical industry illustrates the attractiveness of our value proposition".

About Delenex

Delenex was created in September 2009 as a spin-off from ESBATech (now part of Alcon, the eye care division of Novartis), and is the exclusive licensee for any non-ophthalmic uses of ESBATech's products and IPR pre-dating the spin-off. Delenex' lead compound is DLX105, a small-size, highly tissue-penetrant anti- TNFalpha antibody that the company intends to develop for topical treatment in dermatologic indications. Delenex also has several compounds at pre- clinical stages, among which anti-VEGF, anti-ALK and anti-Abeta antibodies. It is also using its PENTRA® platform to discover new compounds against a selection of dermatology, CNS and inflammation targets. Delenex' strategy is to discover highly potent, selective, soluble and stable compounds for local administration to specific body compartments, such as skin and CNS.

--- End of Message ---

Delenex Therapeutics AG

Wagistrasse 23 Zürich-Schlieren Switzerland

Press Release: http://hugin.info/144623/R/1543399/472808.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Delenex Therapeutics AG via Thomson Reuters ONE

[HUG#1543399]